Valuation: Genexine, Inc.

Market Cap 243B 183M 163M 151M 137M 257M 17.35B 261M 1.81B 712M 9.08B 687M 672M 29.05B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 185M 165M 153M 139M 261M 17.57B 264M 1.84B 721M 9.19B 695M 680M 29.4B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
09-20 Genexine, Inc.(KOSDAQ:A095700) dropped from S&P Global BMI Index CI
09-15 Genexine Presents Preclinical Data For GX-BP1 SOX2 BioPROTAC At 2026 World Conference On Lung Cancer CI
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-15 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
25-09-30 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-09-22 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-03-07 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
24-09-30 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
24-07-04 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
24-06-25 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
24-05-14 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
23-11-14 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
1 day-0.95%
1 week-6.31%
Current month-4.41%
1 month-10.34%
3 months+10.64%
6 months-63.38%
Current year-44.50%
1 week 2,510
Extreme 2510
2,820
1 month 2,510
Extreme 2510
3,625
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
11,870
5 years 2,140
Extreme 2140
55,461.54
10 years 2,140
Extreme 2140
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 2025-03-25
Chief Executive Officer 61 2023-01-26
Corporate Officer/Principal 49 2021-12-31
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 2022-03-28
Director/Board Member 61 2023-01-26
Date Insider Type Main position Quantity % Market Cap. Importance
10/22/24 Others 156,632 0.3773%
10/22/24 Others

Chief Executive Officer

1,691,165 4.0741%
10/22/24 Others 563,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%-6.31%-49.90%-65.38% 89.65M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +2.70%+0.13%+42.62%+102.43% 37.59B
Weighted average by Cap. +3.05%+0.62%+51.67%+122.67%

Financials

2022 2023
Net sales 16.14B 12.17M 10.85M 10.05M 9.1M 17.11M 1.15B 17.35M 121M 47.32M 603M 45.64M 44.67M 1.93B 4.43B 3.34M 2.97M 2.76M 2.5M 4.69M 316M 4.76M 33.08M 12.98M 166M 12.52M 12.25M 529M
Net income -55.97B -42.2M -37.61M -34.87M -31.57M -59.33M -4B -60.17M -418M -164M -2.09B -158M -155M -6.7B -66.87B -50.42M -44.94M -41.66M -37.72M -70.89M -4.78B -71.89M -500M -196M -2.5B -189M -185M -8B
Net Debt 62.14B 46.85M 41.76M 38.71M 35.05M 65.87M 4.44B 66.8M 464M 182M 2.32B 176M 172M 7.43B 2.94B 2.22M 1.98M 1.83M 1.66M 3.12M 210M 3.17M 22M 8.63M 110M 8.33M 8.15M 352M
Projected Income Statement - Annual - Genexine, Inc.
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
26-10-20 ₩2,600.00 -0.95% 72,640
26-10-19 ₩2,625.00 -0.76% 76,448
26-10-16 ₩2,645.00 +2.52% 87,166
26-10-15 ₩2,580.00 -4.09% 186,558
26-10-14 ₩2,690.00 -1.82% 118,273
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Genexine, Inc.
  1. Stock Market
  2. Stocks
  3. A095700 Stock